Phase I Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
The purpose of this Phase 1, open-label, dose-escalation study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with AB122, nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Study ID: AB680CSP0002
Trial Phase: Phase I
Trial Sponsor: Arcus Biosciences, Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, AB680, AB122